Related references
Note: Only part of the references are listed.HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy
Masatoshi Takagi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children
M. Philippe et al.
BONE MARROW TRANSPLANTATION (2016)
Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients
M. Ansari et al.
BONE MARROW TRANSPLANTATION (2016)
Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee
Jeanne Palmer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis
Imke H. Bartelink et al.
Lancet Haematology (2016)
Recent progress in the treatment of infant acute lymphoblastic leukemia
Daisuke Tomizawa
PEDIATRICS INTERNATIONAL (2015)
Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia
K. Koh et al.
LEUKEMIA (2015)
Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization
Jeannine S. McCune et al.
CLINICAL CANCER RESEARCH (2014)
Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children
Yasuhiro Okamoto et al.
PEDIATRIC TRANSPLANTATION (2014)
Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation
Radojka M. Savic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients
M. Ansari et al.
BONE MARROW TRANSPLANTATION (2013)
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial
G. J. Veal et al.
EUROPEAN JOURNAL OF CANCER (2012)
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children
M. Ansari et al.
BONE MARROW TRANSPLANTATION (2010)
Influence of Glutathione S-Transferase A1, P1, M1, T1 Polymorphisms on Oral Busulfan Pharmacokinetics in Children With Congenital Hemoglobinopathies Undergoing Hematopoietic Stem Cell Transplantation
Ronit Elhasid et al.
PEDIATRIC BLOOD & CANCER (2010)
Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation
Imke H. Bartelink et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Busulfan in Hematopoietic Stem Cell Transplantation
Stefan O. Ciurea et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Optimal Prevention of Seizures Induced by High-Dose Busulfan
Andrea L. Eberly et al.
PHARMACOTHERAPY (2008)
Population pharmacokinetics of oral Busulfan in young Japanese children before hematopoietic stem cell transplantation
Hiroyoshi Nakamura et al.
THERAPEUTIC DRUG MONITORING (2008)
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring
G. Vassal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: A final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group
D. Tomizawa et al.
LEUKEMIA (2007)
Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation
Tal Schechter et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Glutathione S-transferase M1 polymorphism:: a risk factor for hepatic venoocclusive disease in bone marrow transplantation
A Srivastava et al.
BLOOD (2004)
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality
A Kashyap et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation
AM Bolinger et al.
BONE MARROW TRANSPLANTATION (2001)
Share Paper
